Status of group B streptococcal vaccine development
Clinical and Experimental Vaccine Research
; : 76-81, 2018.
Article
ي En
| WPRIM
| ID: wpr-739634
المكتبة المسؤولة:
WPRO
ABSTRACT
Streptococcus agalactiae (group B streptococcus, GBS) is a leading causal organism of neonatal invasive diseases and severe infections in the elderly. Despite significant advances in the diagnosis and treatment of GBS infections and improvement in personal hygiene standards, this pathogen is still a global health concern. Thus, an effective vaccine against GBS would augment existing strategies to substantially decrease GBS infection. In 2014, World Health Organization convened the first meeting for consultation on GBS vaccine development, focusing on the GBS maternal immunization program, which was aimed at reducing infections in neonates and young infants worldwide. Here, we review the history of GBS infections, the current vaccine candidates, and the current status of immunogenicity assays used to evaluate the clinical efficacy of GBS vaccines.
Key words
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Polysaccharides
/
Streptococcus
/
Streptococcus agalactiae
/
World Health Organization
/
Vaccines
/
Hygiene
/
Global Health
/
Treatment Outcome
/
Vaccines, Conjugate
/
Immunization Programs
نوع الدراسة:
Diagnostic_studies
/
Guideline
المحددات:
Aged
/
Humans
/
Infant
/
Newborn
اللغة:
En
مجلة:
Clinical and Experimental Vaccine Research
السنة:
2018
نوع:
Article